The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens the outlook for rare disease treatments, INmune Bio announced it has aligned with the UK Medicines and Healthcare products Regulatory Agency (MHRA) on the regulatory path for its drug CORDStrom. The company received written confirmation supporting its plan to submit a Conditional Marketing Authorization application in 2026 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). This alignment follows a scientific advice meeting where the MHRA recognized Phase 2 data as demonstrating clinically meaningful benefits in reducing pain and pruritus for patients.
Sign in to access this content
Sign InThis regulatory milestone positions INmune Bio competitively within the biotech sector focusing on rare dermatological conditions, alongside peers such as Krystal Biotech and Abeona Therapeutics. Per market data, securing a clear regulatory roadmap in the UK often serves as a precursor for expansion into broader European markets, particularly for orphan drugs addressing high unmet medical needs. The MHRA's recognition of the existing clinical evidence package significantly de-risks the asset's path toward potential commercialization.
Regarding market performance, INMB stock stood at $1.45 (close June 18, 2026), having traded between a low of $1.32 and a high of $1.45 in recent sessions according to pre-fetched data. Investors are now looking for updates regarding the commencement of any supplemental trials required before the 2026 filing deadline. Additionally, the broader UK investment climate remains sensitive to macroeconomic shifts, following the recent inflation report showing a 2.8% annual rate as of June 17, 2026.